MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial-Reference-Cited by-同舟云学术

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Published:2015-02-05 Issue:9 Volume:21 Page:2057-2064
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Weller Michael,Tabatabai Ghazaleh,Kästner Bärbel,Felsberg Jörg,Steinbach Joachim P.,Wick Antje,Schnell Oliver,Hau Peter,Herrlinger Ulrich,Sabel Michael C.,Wirsching Hans-Georg,Ketter Ralf,Bähr Oliver,Platten Michael,Tonn Jörg C.,Schlegel Uwe,Marosi Christine,Goldbrunner Roland,Stupp Roger,Homicsko Krisztian,Pichler Josef,Nikkhah Guido,Meixensberger Jürgen,Vajkoczy Peter,Kollias Spyros,Hüsing Johannes,Reifenberger Guido,Wick Wolfgang

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 264 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CREB-induced LINC00473 promotes chemoresistance to TMZ in glioblastoma by regulating O6-methylguanine-DNA-methyltransferase expression via CEBPα binding;Neuropharmacology;2024-02

2. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma;Journal of Neuro-Oncology;2024-01-26

3. Glioblastom – aktuelle Therapiekonzepte;Die Onkologie;2024-01-26

4. ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma;Radiation Oncology;2024-01-22

5. A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial;BMC Cancer;2024-01-15